Britain and America have signed a major trade agreement that will ensure no levies on British pharmaceutical products going into the American market.
The Terms of the Deal
As part of the deal, the UK has agreed to raise funding on drugs through the NHS. This commitment secures that tariffs on these vital goods will be held at zero for a timeframe of the next three years.
This agreement follows previous warnings to significantly raise import taxes on branded drug products, with potential rates floated up to one hundred percent.
"This agreement between the UK reinforces the international landscape for innovative medicines and establishes much-needed fairness to transatlantic medicine commerce," a release declared.
Commercial Significance
Medicines are one of the UK's biggest goods shipped to the America, which is clearly the primary buyer for large UK drugmakers.
Export figures reveal that in the one-year period to the end of September, the UK shipped drugs totaling over eleven billion pounds to the US. This amount made up a significant portion of all goods exports in that period.
"This guarantee secures jobs, stimulates investment and sets the stage for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary commented.
Detailed NHS Changes
The deal entails several specific changes from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to double overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The amount manufacturers must return to the NHS to control costs will be capped at fifteen percent. In the past, rebates were more than 20%.
Broader Context
The deal takes place against a protracted dispute between the pharmaceutical industry and the British authorities over spending levels and approval rates.
This friction were exacerbated by assertions that American consumers were charged significantly more for the identical medicines than consumers in the UK and Europe.
Recently, several significant pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar investments have been pledged toward US facilities.
One official acknowledged that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its resources over the past decade.
